Johnson & Johnson Subsidiary Files for Bankruptcy for the Third Time, Aiming to Shed $100 Billion in Debt, Thousands of Cancer Patients Left Without Recourse!
A unit of Johnson & Johnson filed for bankruptcy Wednesday for the third time, Reuters reported, aiming to advance a $10 billion settlement to end tens of thousands of lawsuits alleging the company's baby powder and other talc products may cause cancer.
More than 62,000 plaintiffs have claimed that Johnson's baby powder and other talc products are contaminated and that they cause ovarian cancer and other types of cancer. In response to the lawsuits, J&J's subsidiary, Red River Talc, has filed for bankruptcy protection in federal bankruptcy court in Houston.
Erik Haas, Johnson & Johnson's vice president of global litigation, said the settlement was "fair and reasonable for all parties," noting that 83 percent of claimants have now supported it.
However, the proposed settlement has sparked controversy among a group of lawyers representing cancer victims. Some opponents said they would move quickly to ask the court to dismiss J&J's bankruptcy filing or have it moved to New Jersey. New Jersey courts have twice rejected J&J's attempts to end litigation through a so-called "Texas two-step" bankruptcy strategy.
Andy Birchfield, a lawyer who opposed the deal, pointed out that Johnson & Johnson is trying to use the bankruptcy system to reduce its liability to tens of thousands of cancer patients.
The report further explained that the "two-step" strategy used by J&J involved transferring debt to a newly formed subsidiary, which subsequently declared bankruptcy. This is a court-supervised asset and debt restructuring process designed to force all plaintiffs to accept a settlement.
Looking for chemical products? Let suppliers reach out to you!
2026-07-09
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
Novo Nordisk Submits Higher Dose of Wegovy One in Three Achieves Over 25 Percent Weight Loss
Recommend Reading
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
The FDA Officially Blesses AI for Liver Drug Development
-
This week, caustic soda prices showed a weak trend (12.8-12.12)
-
Soda Ash Market Remains Stable Amidst Caution
-
In March, the Chinese marine fuel market saw a significant increase
-
Asia’s Plastics Chain Faces a Shock: Tight Naphtha Supply Drives Up Polymer Costs
-
Lula’s Disapproval Hits 2024 Low at 51 Percent Support Surges Among Poor and Women After US Tariff Dispute